It’s the insult Stephen Bailey can’t wait to hear. “You’re boring”, the nurse says, matter-of-factly, and Bailey can’t help ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

HOLTZ IS THE FIRST PERSON IN NEBRASKA AND IOWA TO RECEIVE THE MONOCLONAL ANTIBODY TREATMENT CALLED TEHSIL. IT’S A TREATMENT FOR TYPE ONE DIABETICS TO OFFSET STAGE THREE AND DELAY RELIANCE ON ...

The research, which assessed the benefits of monoclonal antibodies, suggests relief may finally be ahead for millions of Americans with long COVID for whom treatment has remained elusive.

Umair Irfan is a correspondent at Vox writing about climate change, energy policy, and science. He is also a regular contributor to the radio program Science Friday. Prior to Vox, he was a ...